IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
SOUTH SAN FRANCISCO, Calif., May 1, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in an upcoming investor relations event.
加利福尼亚州南旧金山，2024年5月1日 /PRNewswire/ — 致力于发现和开发靶向疗法的精准医学肿瘤学公司IDEAYA Biosciences, Inc.（纳斯达克股票代码：IDYA）宣布参加即将举行的投资者关系活动。
RBC Capital Markets Global Healthcare Conference
Tuesday, May 14th, 2024 at 3:05 PM ET
加拿大皇家银行资本市场全球医疗保健会议
5 月 14 日，星期二第四，2024 年美国东部时间下午 3:05
- Fireside chat with Yujiro S. Hata, Chief Executive Officer, hosted by Gregory Renza, Director and Senior Biotechnology Research Analyst
- 与首席执行官叶田雄二郎的炉边谈话，由董事兼高级生物技术研究分析师Gregory Renza主持
A live audio webcast of the conference event, as permitted by the conference host, will be available at the "Investors/Events" section of the IDEAYA website at and/or through the conference host. A replay of available webcasts will be accessible for 30 days following the live event.
经会议主持人允许，会议活动的网络直播将在IDEAYA网站的 “投资者/活动” 栏目以会议主持人的名义和/或通过会议主持人提供。直播结束后的30天内将提供可用的网络直播的重播。
About IDEAYA Biosciences
关于 IDEAYA 生物科学
IDEAYA is a precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA's approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality – which represents an emerging class of precision medicine targets.
IDEAYA是一家精准医学肿瘤学公司，致力于为使用分子诊断选择的患者群体发现和开发靶向疗法。IDEAYA的方法将识别和验证转化生物标志物的能力与药物发现相结合，以选择最有可能从其靶向疗法中受益的患者群体。IDEAYA正在将其早期研究和药物发现能力应用于合成杀伤力——这是一种新兴的精准医疗靶标。
Forward-Looking Statements
前瞻性陈述
This press release contains forward-looking statements, including, but not limited to, statements related to participation in and/or presentation at certain investor relations events. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see IDEAYA's recent Annual Report on Form 10-K filed on February 20, 2024 and any current and periodic reports filed with the U.S. Securities and Exchange Commission.
本新闻稿包含前瞻性陈述，包括但不限于与参与和/或陈述某些投资者关系活动相关的陈述。IDEAYA没有义务更新或修改任何前瞻性陈述。有关可能导致实际业绩与这些前瞻性陈述中表达的结果不同的风险和不确定性以及与IDEAYA总体业务相关的风险的进一步描述，请参阅IDEAYA最近于2024年2月20日提交的10-K表年度报告以及向美国证券交易委员会提交的任何当前和定期报告。
Investor and Media Contact
IDEAYA Biosciences
Andres Ruiz Briseno
Senior Vice President, Head of Finance and Investor Relations
[email protected]
投资者和媒体联系人
IDEAYA 生物科学
安德烈斯·鲁伊斯·布里塞诺
高级副总裁、财务和投资者关系主管
[电子邮件保护]
SOURCE IDEAYA Biosciences, Inc.
来源 IDEAYA 生物科学公司
译文内容由第三方软件翻译。